Major depressive disorder (MDD) is a leading cause of total disability with inadequate treatment options and unresolved etiology. However, increasing evidence suggests that genetic and environmental vulnerabilities may converge on deficits of GABAergic transmission as a possible, causative core symptom of MDD. Other lines of research point to changes in glutamatergic transmission as being associated with MDD. In particular, subanesthetic doses of the NMDAR antagonist ketamin have rapid and lasting antidepressant effects even in otherwise drug-resistant forms of MDD, pointing to altered function of NMDA receptors. We have established GABA-A receptor gamma2 subunit heterozygous mice as an animal model with excellent construct, face and predictive validity of partially drug resistant MDD. Preliminary data show that GABA-A receptor deficits in gamma2 subunit heterozygous cultures result in markedly reduced expression and function of glutamate receptors. Treatment of mutant cultures with ketamine results in reversal of these deficits. Conversely, mice with GABA-A receptor deficit delimited to forebrain interneurons show a robust antidepressant-like phenotype. We here address the overall hypothesis that MDD is caused by reduced synaptic input from select subtypes of cortical and hippocampal GABAergic interneurons to pyramidal cells. The ensuing GABAergic deficit and altered E/I imbalance, through adaptive mechanisms results in reduced expression and function of ionotropic glutamate receptors, along with reduced functional connectivity of neurons. Transient treatment with NMDA receptor antagonists such as ketamine reverses these deficits and, following dissociation of the drug from the receptor, restores normal glutamatergic transmission. To address this hypothesis we will analyze ketamine-induced changes in expression and function of glutamate receptors and behavior in cultured neurons, brain slices and mice, respectively. We will further test whether chronic treatment with currently used antidepressants has similar effects on glutamatergic transmission. Lastly, we will use genetic deletion of the gamma2 subunit gene in small subsets of interneurons to identify interneuron subclasses that control depression-related behavior. Collectively, our proposal will contribute a major conceptual advance in understanding of the substrate of major depression as well as AD action.

Public Health Relevance

Major depressive disorder (MDD) is a leading cause of total disability with inadequate treatment options and unresolved etiology. We here take advantage of a genetically defined, GABAA receptor-deficient mouse model of MDD to experimentally test novel mechanisms of experimental and conventional antidepressant drugs and to genetically map the cell types that regulate depression-related behavior. These studies will provide a major conceptual advance in understanding of the molecular, cellular and pharmacological substrate regulating depression-related behavior.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH099851-05
Application #
9260949
Study Section
Pathophysiological Basis of Mental Disorders and Addictions Study Section (PMDA)
Program Officer
Nadler, Laurie S
Project Start
2013-04-18
Project End
2018-02-28
Budget Start
2017-03-01
Budget End
2018-02-28
Support Year
5
Fiscal Year
2017
Total Cost
$433,474
Indirect Cost
$137,702
Name
Pennsylvania State University
Department
Biology
Type
Schools of Arts and Sciences
DUNS #
003403953
City
University Park
State
PA
Country
United States
Zip Code
16802
Fuchs, T; Jefferson, S J; Hooper, A et al. (2017) Disinhibition of somatostatin-positive GABAergic interneurons results in an anxiolytic and antidepressant-like brain state. Mol Psychiatry 22:920-930
Du, Keyong; Murakami, Shoko; Sun, Yingmin et al. (2017) DHHC7 Palmitoylates Glucose Transporter 4 (Glut4) and Regulates Glut4 Membrane Translocation. J Biol Chem 292:2979-2991
Fuchs, T; Jefferson, S J; Hooper, A et al. (2017) Disinhibition of somatostatin-positive interneurons by deletion of postsynaptic GABAA receptors. Mol Psychiatry 22:787
Wang, Shaohui; Mott, Kevin R; Wawrowsky, Kolja et al. (2017) Binding of Herpes Simplex Virus 1 UL20 to GODZ (DHHC3) Affects Its Palmitoylation and Is Essential for Infectivity and Proper Targeting and Localization of UL20 and Glycoprotein K. J Virol 91:
Ren, Zhen; Pribiag, Horia; Jefferson, Sarah J et al. (2016) Bidirectional Homeostatic Regulation of a Depression-Related Brain State by Gamma-Aminobutyric Acidergic Deficits and Ketamine Treatment. Biol Psychiatry 80:457-468
Leppä, Elli; Linden, Anni-Maija; Aller, Maria I et al. (2016) Increased Motor-Impairing Effects of the Neuroactive Steroid Pregnanolone in Mice with Targeted Inactivation of the GABAA Receptor ?2 Subunit in the Cerebellum. Front Pharmacol 7:403
Kilpatrick, Casey L; Murakami, Shoko; Feng, Mengyang et al. (2016) Dissociation of Golgi-associated DHHC-type Zinc Finger Protein (GODZ)- and Sertoli Cell Gene with a Zinc Finger Domain-? (SERZ-?)-mediated Palmitoylation by Loss of Function Analyses in Knock-out Mice. J Biol Chem 291:27371-27386
McBain, Chris J; Kittler, Josef; Luscher, Bernhard et al. (2015) GABAergic signaling in health and disease. Neuropharmacology 88:1
Ebersole, Brittany; Petko, Jessica; Woll, Matthew et al. (2015) Effect of C-Terminal S-Palmitoylation on D2 Dopamine Receptor Trafficking and Stability. PLoS One 10:e0140661
Luscher, Bernhard; Fuchs, Thomas (2015) GABAergic control of depression-related brain states. Adv Pharmacol 73:97-144

Showing the most recent 10 out of 14 publications